Rossing P - Search Results

1

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.

Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL; DAPA-CKD Trial Committees and Investigators. Wheeler DC, et al. Among authors: rossing p. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. Lancet Diabetes Endocrinol. 2021. PMID: 33338413 Clinical Trial.

2

Low birth weight. A risk factor for development of diabetic nephropathy?

Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, Parving HH. Rossing P, et al. Diabetes. 1995 Dec;44(12):1405-7. doi: 10.2337/diab.44.12.1405. Diabetes. 1995. PMID: 7589846

3

Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients.

Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving HH. Tarnow L, et al. Among authors: rossing p. Diabetes. 1995 May;44(5):489-94. doi: 10.2337/diab.44.5.489. Diabetes. 1995. PMID: 7729604

4

Unchanged incidence of diabetic nephropathy in IDDM patients.

Rossing P, Rossing K, Jacobsen P, Parving HH. Rossing P, et al. Among authors: rossing k. Diabetes. 1995 Jul;44(7):739-43. doi: 10.2337/diab.44.7.739. Diabetes. 1995. PMID: 7789641

5

On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy.

Nielsen FS, Rossing P, Bang LE, Svendsen TL, Gall MA, Smidt UM, Parving HH. Nielsen FS, et al. Among authors: rossing p. Diabetes. 1995 Jul;44(7):783-9. doi: 10.2337/diab.44.7.783. Diabetes. 1995. PMID: 7789646

6

Prevalence of arterial hypertension in diabetic patients before and after the JNC-V.

Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Tarnow L, et al. Among authors: rossing p. Diabetes Care. 1994 Nov;17(11):1247-51. doi: 10.2337/diacare.17.11.1247. Diabetes Care. 1994. PMID: 7821162

7

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.

Parving HH, Rossing P. Parving HH, et al. Among authors: rossing p. Curr Opin Nephrol Hypertens. 1994 May;3(3):292-300. doi: 10.1097/00041552-199405000-00010. Curr Opin Nephrol Hypertens. 1994. PMID: 7922255 Review.

8

Monitoring kidney function in diabetic nephropathy.

Rossing P, Astrup AS, Smidt UM, Parving HH. Rossing P, et al. Diabetologia. 1994 Jul;37(7):708-12. doi: 10.1007/BF00417696. Diabetologia. 1994. PMID: 7958543

9

Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.

Nielsen FS, Rossing P, Gall MA, Skøtt P, Smidt UM, Parving HH. Nielsen FS, et al. Among authors: rossing p. Diabetes. 1994 Sep;43(9):1108-13. doi: 10.2337/diab.43.9.1108. Diabetes. 1994. PMID: 8070610 Clinical Trial.

10

Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.

Gall MA, Rossing P, Kofoed-Enevoldsen A, Nielsen FS, Parving HH. Gall MA, et al. Among authors: rossing p. Diabetologia. 1994 Feb;37(2):195-201. doi: 10.1007/s001250050093. Diabetologia. 1994. PMID: 8163055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

742 results

Search Page